Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects

Tumor recurrence rate after surgery or ablation of hepatocellular carcinoma (HCC) is as high as 70%. However, there are no widely accepted adjuvant therapies; therefore, no treatment has been recommended by guidelines from the American Association for the Study of Liver Disease or the European Assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiao-Dong, Li, Kang-Shuai, Sun, Hui-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452398/
https://www.ncbi.nlm.nih.gov/pubmed/32884990
http://dx.doi.org/10.1016/j.gendis.2020.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452398/
https://www.ncbi.nlm.nih.gov/pubmed/32884990
http://dx.doi.org/10.1016/j.gendis.2020.02.002

Ejemplares similares